Katherine Wilkins, PA
Physician Assistant · Sunnyvale, TXNPI 1700950334
Payments from drug & device makers
Across 266 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$617
- AbbVie$424
- AstraZeneca$423
- Lilly USA, LLC$403
- Otsuka America Pharmaceutical, Inc.$398
- Pfizer$322
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,931100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $617 |
| AbbVie | 28 | $424 |
| AstraZeneca | 16 | $423 |
| Lilly USA, LLC | 27 | $403 |
| Otsuka America Pharmaceutical, Inc. | 16 | $398 |
| Pfizer | 17 | $322 |
| Astellas Pharma US Inc | 11 | $255 |
| GSK | 14 | $225 |
| Boehringer Ingelheim | 11 | $207 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $196 |
| Sanofi-aventis U.S. LLC | 8 | $148 |
| Merck | 8 | $144 |
| Exact Sciences | 8 | $140 |
| Bayer | 6 | $118 |
| Dexcom, Inc. | 6 | $114 |
| Abbott | 4 | $92 |
| Amgen | 4 | $73 |
| Dynavax Technologies Corporation | 4 | $72 |
| Antares Pharma, Inc. | 4 | $62 |
| Lundbeck LLC | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Ironwood Pharmaceuticals, Inc | 2 | $40 |
| Corcept Therapeutics | 1 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Roche Diagnostics Corporation | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Genentech USA, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,931 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 114 | $120,298 |
| JardianceEmpagliflozin | 80 | $85,908 |
| EliquisApixaban | 56 | $43,829 |
| MounjaroTirzepatide | 25 | $33,680 |
| FarxigaDapagliflozin Propanediol | 28 | $28,354 |
| TrulicityDulaglutide | 21 | $26,406 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $22,678 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $15,090 |
| XareltoRivaroxaban | 20 | $14,159 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $12,978 |
| JanuviaSitagliptin Phosphate | 14 | $11,114 |
| MyrbetriqMirabegron | 12 | $9,639 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,796 |
| Levocetirizine Dihydrochloride | 429 | $2,837 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 129 | $2,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $617 | $120,298114 claims |
| Boehringer IngelheimJardiance | $207 | $85,90880 claims |
| Lilly USA, LLCMounjaro, Trulicity | $403 | $60,08646 claims |
| PfizerEliquis | $322 | $43,82956 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $423 | $43,44451 claims |
| GSKTrelegy Ellipta | $225 | $22,67833 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $148 | $12,97813 claims |
| MerckJanuvia | $144 | $11,11414 claims |
| Astellas Pharma US IncMyrbetriq | $255 | $9,63912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $196 | $6,79612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Sunnyvale
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.